PIK3CA immunoreactivity was notably higher in older patients with bladder cancer (P = 0.045), with more advanced clinical stage (P = 0.016), and higher rate positive lymph node metastasis (P = 0.031) (Figure 1E and Supplementary Table S1). Here, PIK3CA is linked to urinary bladder cancer.